1. Search Result
Search Result
Results for "

alzheimers

" in MedChemExpress (MCE) Product Catalog:

1812

Inhibitors & Agonists

13

Screening Libraries

20

Fluorescent Dyes

22

Biochemical Assay Reagents

149

Peptides

55

Inhibitory Antibodies

289

Natural
Products

79

Isotope-Labeled Compounds

5

Antibodies

13

Click Chemistry

12

Oligonucleotides

3

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W015229
    3-Indolepropionic acid
    5+ Cited Publications

    Indole-3-propionic acid; 3-IPA

    Endogenous Metabolite Reactive Oxygen Species (ROS) Neurological Disease Metabolic Disease
    3-Indolepropionic acid is shown to be a powerful antioxidant and has potential in the treatment for Alzheimer’s disease.
    3-Indolepropionic acid
  • HY-D0972
    Thioflavine S
    Maximum Cited Publications
    28 Publications Verification

    Thioflavin S; Direct Yellow 7

    Fluorescent Dye Others
    Thioflavine S is a fluorescent histochemical marker of dense core senile plaques. Thioflavine S can be used for Alzheimer's research .
    Thioflavine S
  • HY-P1061
    Colivelin
    Maximum Cited Publications
    92 Publications Verification

    STAT Amyloid-β Neurological Disease
    Colivelin is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro . Colivelin exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease . Colivelin has the potential for the treatment of alzheimer's disease and ischemic brain injury
    Colivelin
  • HY-13410
    Xanomeline oxalate
    5+ Cited Publications

    LY246708 oxalate

    mAChR Neurological Disease
    Xanomeline oxalate (LY246708 oxalate) is a potent and selective muscarinic receptor agonist (SMRA) and stimulates phosphoinositide hydrolysis in vivo. Xanomeline oxalate can be used for the research of Alzheimer’s disease .
    Xanomeline oxalate
  • HY-B1488
    Tacrine hydrochloride
    5+ Cited Publications

    Cholinesterase (ChE) iGluR Neurological Disease
    Tacrine hydrochloride is a potent brain-penetrant inhibitor of both AChE and BChE, with IC50s of 31 nM and 25.6 nM, respectively. Tacrine hydrochloride is also a NMDAR inhibitor, with an IC50 of 26 μM. Tacrine hydrochloride can be used for the research of Alzheimer’s disease .
    Tacrine hydrochloride
  • HY-138935
    Iclepertin
    3 Publications Verification

    BI-425809

    GlyT Neurological Disease
    Iclepertin (BI-425809) is a potent, selective and orally active glycine transporter 1 (GlyT1) inhibitor. Iclepertin is inactive against GlyT2. Iclepertin can be used for Alzheimer disease and schizophrenia research .
    Iclepertin
  • HY-111263
    NIAD-4
    1 Publications Verification

    Fluorescent Dye Amyloid-β Others
    NIAD-4 is a blood-brain barrier permeable fluorophore for optical imaging of amyloid-β () in the central nervous system (CNS) for Alzheimer’s disease (AD). NIAD-4 binds to the same Aβ site with the binding affinity (Ki) of 10 nM .
    NIAD-4
  • HY-P1061A
    Colivelin TFA
    Maximum Cited Publications
    92 Publications Verification

    STAT Amyloid-β Apoptosis Neurological Disease
    Colivelin TFA is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro . Colivelin TFA exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease . Colivelin TFA has the potential for the treatment of alzheimer's disease and ischemic brain injury .
    Colivelin TFA
  • HY-114616

    Tau Protein Fluorescent Dye Neurological Disease
    PBB3 is a tracer of tau PET. PBB3 can be used to detect levels of tau protein in Alzheimer's disease and non-Alzheimer's disease .
    PBB3
  • HY-117259
    Valiltramiprosate
    1 Publications Verification

    ALZ-801

    Amyloid-β Neurological Disease
    ALZ-801 is a potent and orally available small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated proagent of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound . ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease .
    Valiltramiprosate
  • HY-Y0399

    Norvaline

    Amyloid-β TNF Receptor Arginase Neurological Disease Metabolic Disease
    L-Norvaline is the inhibitor for arginase, that promotes the production of NO, reduces oxidative stress, improves insulin resistance, and exhibits antioxidant and anti-hyperglycemic effects. L-Norvaline can be used in research of Alzheimer’s disease .
    L-Norvaline
  • HY-10933
    CX516
    2 Publications Verification

    BDP 12

    iGluR Neurological Disease
    CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI) .
    CX516
  • HY-109052
    Atabecestat
    1 Publications Verification

    JNJ-54861911

    Beta-secretase Neurological Disease
    Atabecestat (JNJ-54861911) is a potent brain-penetrant and orally active β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, achieves robust and high CSF Aβ reduction. Atabecestat s tolerated and displays a sustained pharmacokinetic (PK) and pharmacodynamic (PD) characteristics. Atabecestat has the potential for Alzheimer's Disease treatment .
    Atabecestat
  • HY-B0949
    Protriptyline hydrochloride
    2 Publications Verification

    Cholinesterase (ChE) Amyloid-β Neurological Disease
    Protriptyline hydrochloride is a potent tricyclic antidepressant (TCA). Protriptyline hydrochloride inhibits AChE activity with an IC50 value of 0.06 mM and inhibits Aβ self-assembly. Protriptyline hydrochloride can be used for the study of depression and Alzheimers disease .
    Protriptyline hydrochloride
  • HY-100550
    MSDC 0160
    4 Publications Verification

    Mitoglitazone; CAY10415

    Insulin Receptor Mitochondrial Metabolism Neurological Disease Endocrinology
    MSDC 0160 (Mitoglitazone) is a mitochondrial target of thiazolidinediones (mTOT)-modulating insulin sensitizer and a modulator of mitochondrial pyruvate carrier (MPC). MSDC 0160 is a thiazolidinedione (TZD) with antidiabetic and neuroprotective activities. MSDC 0160 has the potential for Alzheimer′s disease .
    MSDC 0160
  • HY-13779

    Monoamine Oxidase Dopamine Transporter Neurological Disease
    (E/Z)-J147 is an exceptionally potent, orally active, neuroprotective agent for cognitive enhancement. (E/Z)-J147 can readily pass the blood brain barrier (BBB). (E/Z)-J147 can inhibit monoamine oxidase B (MAO B) and the dopamine transporter with EC50 values of 1.88 μM and 0.649 μM, respectively. (E/Z)-J147 has potential for the study of Alzheimer’s disease (AD) .
    (E/Z)-J147
  • HY-N8376

    (±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone

    Amyloid-β mAChR Cholinesterase (ChE) Neurological Disease
    Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) is a potent amyloid β (Aβ) inhibitor. Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) increases the expression of acetylcholine (ACh) levels, choline acetyltransferase (ChAT) activity, and ChAT gene induced by Aβ (1-42). Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) decreases in acetyl cholinesterase (AChE) activity and AChE gene expression induced by Aβ (1-42). Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) increases muscarinic M1 receptor gene expression and muscarinic M1 receptor binding activity. Fustinis ((±)-Fustin; 3,7,3',4'-Tetrahydroxyflavanone) can be used for Alzheimer's disease research .
    Fustin
  • HY-132582

    IONIS-MAPTRx; BIIB080; ISIS 814907

    Tau Protein Neurological Disease
    Diranersen (IONIS-MAPTRx) is an antisense oligonucleotide that targets the human MAPT gene to inhibit the production of tau protein. Diranersen can be used in research related to Alzheimer's disease and tauopathies .
    Diranersen
  • HY-122487

    BHV-4157

    mGluR Neurological Disease Cancer
    Troriluzole, a third-generation, tripeptide proagent of Riluzole (HY-B0211), is an orally active glutamate modulator. Troriluzole reduces synaptic glutamate level and increases the synaptic glutamate absorption. Troriluzole has the potential for Alzheimer disease and generalized anxiety disorder (GAD) .
    Troriluzole
  • HY-130344
    SKF 83959
    1 Publications Verification

    Dopamine Receptor Sigma Receptor Neurological Disease
    SKF83959 is a potent and selective dopamine D1-like receptor partial agonist. SKF83959 Ki values for rat D1, D5, D2 and D3 receptors are 1.18, 7.56, 920 and 399 nM, respectively. SKF83959 is a potent allosteric modulator of sigma (σ)-1 receptor. SKF83959 belongs to benzazepine family and has improvements on cognitive dysfunction. SKF83959 can be used for the research of Alzheimer's disease and depression .
    SKF 83959
  • HY-119173

    Amyloid-β Neurological Disease
    PBD-150 is a human glutaminyl cyclase (hQC) Y115E-Y117E variant inhibitor, with a Ki value of 490 nM .
    PBD-150
  • HY-16361A

    CGP3466B; CGP3446 maleate; TCH346 maleate

    Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology
    Omigapil maleate (CGP3466B), an orally active GAPDH nitrosylation inhibitor, abrogates Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice. Omigapil maleate has the potential for the research of Alzheimer's disease. Omigapil maleate is a apoptosis inhibitor. Omigapil maleate can be used for the research of congenital muscular dystrophy (CMD). Omigapil maleate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups .
    Omigapil maleate
  • HY-P1047

    [Pro18, Asp21] β-Amyloid (17-21)

    Amyloid-β Neurological Disease
    β-Sheet Breaker Peptide iAβ5 is an effective brain amyloid-β (Abeta) degrader. Abeta deposits are associated with Alzheimer's disease (AD), and the related toxicity arises from its β-sheet conformation and aggregation. β-Sheet Breaker Peptide iAβ5 can repeatedly induce the degradation of fibrillary amyloid deposits in vivo. Therefore, β-Sheet Breaker Peptide iAβ5 can prevent and/or reverse neuronal contraction caused by Abeta and reduce the range of interleukin IL-1beta positive microglial-like cells around Abeta deposits. β-Sheet Breaker Peptide iAβ5 can reduce the size and/or number of brain amyloid plaques in AD. β-Sheet Breaker Peptide iAβ5 is labeled with a hydrophobic benzyl alcohol (HBA) tag and shows a bright blue color under acidic conditions, which can be used for quantitative determination.
    β-Sheet Breaker Peptide iAβ5
  • HY-136500

    PGH2

    Endogenous Metabolite Amyloid-β Neurological Disease Inflammation/Immunology
    Prostaglandin H2 (PGH2) is an endothelium-derived contracting factor. Prostaglandin H2 can cause vasoconstriction. Prostaglandin H2 is the common precursor of all PGs and is produced by several cells that express cyclooxygen-ases. Prostaglandin H2 can activate PGD2 receptors CRTH2 and DP via interacting directly with the receptors and/or by giving rise to PGD2 after catalytic conversion by plasma proteins. Prostaglandin H2 can induce eosinophils migration and inhibit platelet aggregation. Prostaglandin H2 can accelerate the formation of dimers and higher oligomers of amyloid β1-42. Prostaglandin H2 can be used for the researches of inflammation and neurological disease, such as Alzheimer disease .
    Prostaglandin H2
  • HY-147060

    DYRK Neurological Disease
    Dyrk1A-IN-3 (Compound 8b), a highly selective dual-specificity tyrosine-regulated kinase 1A (DYRK1A) inhibitor, maintains high levels of DYRK1A binding affinity (IC50=76 nM). Dyrk1A-IN-3 can be used for the research of neurodegenerative disorders such as Alzheimer’s Disease, Huntington’s Disease, and Parkinson’s Disease .
    Dyrk1A-IN-3
  • HY-108312A

    Caspase Neurological Disease
    Ac-VEID-CHO (TFA) is a peptide-derived caspase inhibitor and has potency of inhibition for Caspase-6, Caspase-3 and Caspase-7 with IC50 values of 16.2 nM, 13.6 nM and 162.1 nM, respectively. Ac-VEID-CHO (TFA) can be used for the research of neurodegenerative conditions including Alzheimer’s and Huntington’s disease .
    Ac-VEID-CHO TFA
  • HY-10096

    GSK-3 Neurological Disease
    TCS2002 (Compound 9b) is a highly selective, orally bioavailable and potent GSK-3β inhibitor with the IC50 of 35 nM. TCS2002 shows good pharmacokinetic profiles including favorable BBB penetration. TCS2002 can be used for the research of Alzheimer’s disease .
    TCS2002
  • HY-10400

    TV-3326 hemitartrate

    Monoamine Oxidase Cholinesterase (ChE) Neurological Disease
    Ladostigil (TV-3326) hemitartrate is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO) that can cross the blood-brain barrier, with IC50s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil hemitartrate exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil hemitartrate can be used for the research of depression and Alzheimer's disease . Ladostigil (hemitartrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Ladostigil hemitartrate
  • HY-117924

    Autophagy enhancer-67

    Autophagy Neurological Disease
    AUTEN-67 (Autophagy enhancer-67) is an orally active autophagy enhancer and MTMR14 inhibitor. AUTEN-67 has anti-aging and neuroprotective effects. AUTEN-67 protects neurons from stress-induced cell death. AUTEN-67 also restores nesting behavior in a mice model of Alzheimer disease .
    AUTEN-67
  • HY-10399A

    TV-3326 hydrochloride

    Monoamine Oxidase Cholinesterase (ChE) Neurological Disease
    Ladostigil (TV-3326) hydrochloride is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC50s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil hydrochloride exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease . Ladostigil (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Ladostigil hydrochloride
  • HY-167843

    Akt Autophagy PTEN Amyloid-β Antibiotic Bacterial Fungal Infection Neurological Disease
    Alborixin is a polycyclic polyether ionophore Antibiotic. Alborixin is isolated from cultures of Streptomyces albus. Alborixin induces Autophagy via PTEN-mediated inhibition of the AKT pathway, thereby clearing Amyloid-β. Alborixin exhibits activity against Gram-positive bacteria and fungi. Alborixin can be used in the research of Alzheimer's disease .
    Alborixin
  • HY-101710

    GLN-1062

    Drug Intermediate Neurological Disease
    Benzgalantamine (GLN-1062) is a pro-agent of galantamine, used for the treatment for Alzheimer’s disease.
    Benzgalantamine
  • HY-150053
    JNK-IN-11
    1 Publications Verification

    JNK Neurological Disease
    JNK-IN-11 (compound 1) is a potent JNK inhibitor with an IC50 value of 2.2, 21.4, 1.8 µM for JNK1, JNK2, JNK3, respectively. JNK-IN-11 has the potential for the research of alzheimer and parkinson disease .
    JNK-IN-11
  • HY-N4206

    Cholinesterase (ChE) Neurological Disease
    Leptomerine, an alkaloid from stems of Esenbeckia leiocarpa Engl. (Rutaceae) as potential treatment for Alzheimer Disease. Leptomerine inhibits acetyl cholinesterase (AChE) with an IC50 of 2.5 μM. Anticholinesterasic activity .
    Leptomerine
  • HY-111560

    Potassium Channel Neurological Disease
    IQM-266 is a Downstream Regulatory Element Antagonist Modulator (DREAM) ligand with a KD of 4.63 μM. IQM-266 inhibits the KV4.3/DREAM current in a concentration-, voltage-, and time-dependent-manner. IQM-266 also modulates A-type outward potassium currents (IA) from rat dorsal root ganglia (DRG) neurons. IQM-266 can be used for neurological disease research, such as Alzheimer’s disease and Huntington's disease (HD) .
    IQM-266
  • HY-10399

    TV-3326

    Monoamine Oxidase Cholinesterase (ChE) Neurological Disease
    Ladostigil (TV-3326) is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC50s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease . Ladostigil is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Ladostigil
  • HY-103412
    SKF 83959 hydrobromide
    1 Publications Verification

    Dopamine Receptor Sigma Receptor Neurological Disease
    SKF83959 hydrobromide is a potent and selective dopamine D1-like receptor partial agonist. SKF83959 hydrobromide Ki values for rat D1, D5, D2 and D3 receptors are 1.18, 7.56, 920 and 399 nM, respectively. SKF83959 hydrobromide is a potent allosteric modulator of sigma (σ)-1 receptor. SKF83959 hydrobromide belongs to benzazepine family and has improvements on cognitive dysfunction. SKF83959 hydrobromide can be used for the research of Alzheimer's disease and depression .
    SKF 83959 hydrobromide
  • HY-133025

    Somatostatin Receptor Neurological Disease
    FK962 is an enhancer of somatostatin release, exerts cognitive-enhancing actions. Anti-dementia properties .
    FK962
  • HY-110176

    GlyT Neurological Disease
    ASP2535 is a potent, orally bioavailable, selective, brain permeable and centrally-active glycine transporter-1 (GlyT1) inhibitor. ASP2535 can improve cognitive impairment in animal models of schizophrenia and Alzheimer's disease .
    ASP2535
  • HY-Y0399R

    Amyloid-β Reference Standards TNF Receptor Arginase Neurological Disease Metabolic Disease
    L-Norvaline (Standard) is the analytical standard of L-Norvaline (HY-Y0399). This product is intended for research and analytical applications. L-Norvaline is the inhibitor for arginase, that promotes the production of NO, reduces oxidative stress, improves insulin resistance, and exhibits antioxidant and anti-hyperglycemic effects. L-Norvaline can be used in research of Alzheimer’s disease .
    L-Norvaline (Standard)
  • HY-100723

    Amyloid-β Neurological Disease
    THK-523 has demonstrated its high affinity and selectivity for tau pathology both in vitro and in vivo. 18F-THK523 is a potent tau imaging radiotracer. 18F-THK523 is a potent in vivo tau imaging ligand for Alzheimer's disease .
    THK-523
  • HY-144389

    Cholinesterase (ChE) Amyloid-β Neurological Disease
    hAChE/Aβ1-42-IN-1 (Compound 16) is a potent inhibitor of hAChE and Aβ1-42 aggregation. hAChE/Aβ1-42-IN-1 shows acceptable relative safety upon hepG2 cell line and excellent BBB penetration with wide safety margin. hAChE/Aβ1-42-IN-1 has the potential for the research of Alzheimer disease (AD) .
    hAChE/Aβ1-42-IN-1
  • HY-172427

    Vasopressin Receptor Neurological Disease
    Elsovaptan is the antagonist for vasopressin receptor that can be used in researchs of Alzheimer disease .
    Elsovaptan
  • HY-P1362A

    Amyloid β Peptide (42-1)(human) TFA

    Amyloid-β Neurological Disease
    β-Amyloid (42-1), human TFA is the inactive form of Amyloid β Peptide (1-42). β-Amyloid (42-1), human TFA is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease .
    β-Amyloid (42-1), human TFA
  • HY-P1051

    Amyloid β-Protein (12-28)

    Amyloid-β Neurological Disease
    β-Amyloid (12-28) (Amyloid β-Protein (12-28)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) shows aggregation properties. β-Amyloid (12-28) has the potential for Alzheimer’s disease research .
    β-Amyloid (12-28)
  • HY-B0949A

    Cholinesterase (ChE) Amyloid-β Neurological Disease
    Protriptyline is a potent tricyclic antidepressant (TCA). Protriptyline inhibits AChE activity with an IC50 value of 0.06 mM and inhibits Aβ self-assembly. Protriptyline can be used for the study of depression and Alzheimers disease .
    Protriptyline
  • HY-145712

    FKBP Cancer
    ElteN378 is an inhibitors of FKBP12e. ElteN378 can be used in study Alzheimer disease, Parkinson disease, Amyotrophic Lateral Sclerosis, proliferation disorders and cancer .
    ElteN378
  • HY-168563

    Cholinesterase (ChE) FAAH Neurological Disease
    BuChE-IN-15 (compound D12) is a selective BuChE/FAAH dual inhibitor with and show IC50 values of 81 and 400 nM for hBuChE and hFFAH, respectively. BuChE-IN-15 possesses good BBB penetration, and shows neuroprotection.BuChE-IN-15 can be used for study of Alzheimer .
    BuChE-IN-15
  • HY-P991536

    Amyloid-β Neurological Disease
    KHK6640 is a humanized anti-amyloid beta oligomer-specific antibody. KHK6640 demonstrates high potency and efficacy for cognitive improvement in several rodent Alzheimer’s models. KHK6640 can be studied in research for neurological diseases such as Alzheimer’s disease .
    KHK6640
  • HY-N15649

    Cholinesterase (ChE) Neurological Disease
    Ostruthol is a coumarin and a potent inhibitor of AChE. Ostruthol can be studied in research on Alzheimer’s disease .
    Ostruthol

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: